MABC202
Anti-APC Antibody, clone FE9
clone FE9, from mouse
Synonym(s):
Adenomatous polyposis coli protein, Protein APC, Deleted in polyposis 2.5
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
biological source
mouse
Quality Level
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
FE9, monoclonal
species reactivity
human
technique(s)
western blot: suitable
isotype
IgG1κ
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... APC(324)
Related Categories
General description
Adenomatous polyposis coli protein (APC) is a ubiquitous multidomain protein that has a well documented role as a tumor suppressor. The mechanism of APC-mediated tumor suppression is still an area of active investigation; however, several studies suggest that APC is a negative regulator of the Wnt signaling pathway as it downregulates β-catenin via interactions with Axin/GSK3-β complex, thereby preventing transcription of genes such as MYC that contribute to cell proliferation. Defective APC proteins contribute to the initiation and proliferation of various types of cancers, including familial adenomatous polyposis. However, other studies have shown that APC interacts with a range of other proteins such as the EB1 microtubule-binding proteins, to regulate other processes such as cell migration.
Specificity
This antibody recognizes the N-terminus of APC.
Immunogen
Linear peptide corresponding to the N-terminus of human APC.
Application
Anti-APC Antibody, clone FE9 is an antibody against APC for use in Western Blotting.
Quality
Evaluated by Western Blot in SW480 cell lysate.
Western Blot Analysis: 0.5 µg/mL of this antibody detected APC in 10 µg of SW480 cell lysate.
Western Blot Analysis: 0.5 µg/mL of this antibody detected APC in 10 µg of SW480 cell lysate.
Target description
~147 kDa observed. Uniprot describes the full length protein at ~312 kDa This antibody was shown to detect the truncated form at ~147 kDa
Physical form
Format: Purified
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Not finding the right product?
Try our Product Selector Tool.
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Maria Paz Zafra et al.
Nature biotechnology, 36(9), 888-893 (2018-07-04)
CRISPR base editing enables the creation of targeted single-base conversions without generating double-stranded breaks. However, the efficiency of current base editors is very low in many cell types. We reengineered the sequences of BE3, BE4Gam, and xBE3 by codon optimization
Inducible in vivo genome editing with CRISPR-Cas9.
Dow, LE; Fisher, J; O'Rourke, KP; Muley, A; Kastenhuber, ER; Livshits, G; Tschaharganeh et al.
Nature Biotechnology null
Weiran Feng et al.
Proceedings of the National Academy of Sciences of the United States of America, 118(32) (2021-08-07)
The increasing complexity of different cell types revealed by single-cell analysis of tissues presents challenges in efficiently elucidating their functions. Here we show, using prostate as a model tissue, that primary organoids and freshly isolated epithelial cells can be CRISPR
Thai Q Tran et al.
Nature cancer, 1(3), 345-358 (2020-08-25)
Genetic-driven deregulation of the Wnt pathway is crucial but not sufficient for colorectal cancer (CRC) tumourigenesis. Here, we show that environmental glutamine restriction further augments Wnt signaling in APC mutant intestinal organoids to promote stemness and leads to adenocarcinoma formation
Philipp Rathert et al.
Nature, 525(7570), 543-547 (2015-09-15)
Following the discovery of BRD4 as a non-oncogene addiction target in acute myeloid leukaemia (AML), bromodomain and extra terminal protein (BET) inhibitors are being explored as a promising therapeutic avenue in numerous cancers. While clinical trials have reported single-agent activity
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service